Abstract
Nocardia disease is a rare opportunistic infection typically seen in immunocompromised patients, but it can be life-threatening even in healthy individuals. This case report describes a 78-year-old male farmer whose lung lesions, initially suspected to be cancerous by both clinicians and artificial intelligence (AI), were correctly identified as Nocardia otitidiscaviarum through metagenome next-generation sequencing (mNGS). This rapid diagnosis allowed for targeted antimicrobial therapy, leading to a full recovery.
The Diagnostic Challenge: A "Great Masquerader"
Pulmonary nocardiosis (PN) often presents a significant diagnostic hurdle. Nocardia, an aerobic, slow-growing bacterium found in soil, frequently mimics lung cancer or tuberculosis on CT scans, showing solid lesions with characteristic "burr signs."
In this case, a previously healthy patient presented with fever and lung lesions. Despite escalating empirical treatments, his condition deteriorated into septic shock. Traditional sputum cultures remained negative. Notably, an AI diagnostic tool (YITU) also misidentified the lesions as malignant, illustrating a critical "blind spot" in software trained primarily on common clinical patterns.
Methods: Leveraging mNGS for Rapid Identification
To resolve the diagnostic deadlock, clinicians performed a needle biopsy of the largest lung lesion, withdrawing pus for analysis. While traditional cultures are slow and often insensitive for Nocardia, the team employed metagenome next-generation sequencing (mNGS).
Unlike standard cultures, mNGS sequences all nucleic acids in a sample and compares them against vast genomic databases. This "hypothesis-free" approach allows for the identification of rare or fastidious organisms without prior clinical suspicion. In this instance, mNGS provided results in just a few days, whereas traditional cultures can take up to two weeks.
Key Results and Clinical Outcome
The mNGS report identified Nocardia otitidiscaviarum at a concentration of 7,504 copies/mL. Crucially, the report included antibiotic susceptibility data, which is vital given the varying resistance profiles among Nocardia species.
Based on these findings, the medical team pivoted to a targeted regimen of oral compound sulfamethoxazole and intravenous meropenem. The patient’s fever resolved within 48 hours. Follow-up imaging confirmed the effectiveness of the treatment:
- One month: Significant reduction in lung shadows.
- Five months: Complete absorption of the lesions.
Key Insights
- AI Limitations: The AI's failure to distinguish between rare infection and malignancy highlights the need for clinical oversight and the integration of advanced molecular diagnostics.
- Diagnostic Speed: The 10-day advantage provided by mNGS over traditional culture was likely life-saving in the context of the patient's septic shock.
- Precision Medicine: mNGS not only identified the pathogen but also guided the selection of effective antibiotics, moving beyond empirical "broad-spectrum" guesswork.
Limitations and Future Outlook
As a single case report, these findings may not be universally applicable to all PN cases. The primary barriers to widespread mNGS adoption remain its higher cost and limited availability in many clinical settings. However, the authors advocate for the earlier use of mNGS in cases of "fever of unknown origin" or suspected malignancy that fails to respond to initial therapy, potentially transforming the management of complex co-infections.
Summary updated